Alzheimers Disease Drug Market Report 2025 (Global Edition)

Global Alzheimers Disease Drug Market Report 2025 Market Size Split by Type (Centrally Acting AChE Inhibintors, NMDA Antagonists), by Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy),...

Alzheimers Disease Drug Market Report Description

We have various report editions of Alzheimers Disease Drug Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Alzheimers Disease Drug Market Insights Video

• Majority of global manufacturers of Alzheimer’s Disease Drug are demonstrating world-class sustainable practices and are attracting a lot of capital. New product launches, pipeline products and R&D activities are some of the key strategies adopted by the key players to acquire a greater market share.
• The report involves complete profiling of below mentioned players which are identified among the top players. Numerous medicines for the symptomatic management of Alzheimer's disease are available in a fragmented market. Numerous suppliers are being forced to create new vaccinations due to the disease's high incidence and the demand for extremely effective therapies.

News

• September 2022

Eisai Co., Ltd. and Biogen Inc. completed the submission of Biologics License Application to U.S. Food and Drug Administration for lecanemab:
Eisai Co., Ltd. and Biogen Inc. announced that it has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain.

• July 2021

AbbVie plans to move next-gen Aduhelm hopeful for Alzheimer's into the clinic
AbbVie has planned to push an Alzheimer’s disease candidate that potentially has a better safety profile into the clinic by year’s end or early next year. The company is pursuing a range of possible ways to tackle Alzheimer’s. Those include AL002, a monoclonal antibody trying to enhance the activity of the TREM2 gene, and AL003, which targets a genetic link to the disease, called sialic acid binding Ig-like lectin 3 (SIGLEC 3).

• November 2017

Novartis and Amgen have entered into collaboration with Banner Alzheimer's Institute
Novartis, Amgen and the Banner Alzheimer's Institute (BAI) has expanded collaboration in which the companies initiated a new trial - the Alzheimer's Prevention Initiative (API) Generation Study 2. This trial follows the launch of the Generation Study 1, and thus it determined whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer's disease symptoms in a high-risk population.

• November 2022

Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease
Roche announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia, collectively called early Alzheimer’s disease. Gantenerumab was well tolerated, including the subcutaneous administration.

Top Companies Market Share in Alzheimers Disease Drug Industry: (In no particular order of Rank)

• Eisai
• Pfizer
• Novartis
• Shire
• Janssen
• Forest Laboratories
• H. Lundbeck
• Merz
• Daiichi Sankyo
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

As per our analysis, market share for Alzheimer’s Disease Drug in North America is over 40%. Hence North America is dominating the market with USD XX Bn in 2021. High number of people in America shows symptoms for Alzheimer’s disease and this number is continuously increasing. Thus, demand for AD drugs is significant in North America. Further, U.S. Food and Drug Administration approved Aduhelm recently for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans.
Two years of COVID-19 pandemic have shifted the dynamics in the US healthcare value chain. Innovation and growth continued unabated in services. acceleration of value-based care models and increasing application of technology across the healthcare industry are likely to continue in the long term. All these parameters driven North America market for Alzheimer’s Disease Drug.
Asia-Pacific Alzheimer’s Disease Drug market is set to show significant growth rate in coming years
Asia-Pacific Alzheimer’s Disease Drug market is set to display growth at a high compound annual growth rate as countries/territories on multiple metrics, New Zealand, Australia, Hong Kong, and Japan along with China and India has high potential for healthcare sector. Growing population, and increasing awareness has stimulated growth for this market. Further, like U.S., China and Japan are also experiencing growth in its geriatric population.
Alzheimer’s Disease Drug is also seeing a rapid rise in popularity in Europe, partly due to an overall growth in the European geriatric population.

The current report Scope analyzes Alzheimers Disease Drug Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Alzheimers Disease Drug Market Analysis

Type Segment Analysis of Alzheimers Disease Drug Market

This report categorizes competitors in the pharmaceutical and healthcare market based on their product offerings and business models. It includes key details such as definitions, benefits, applications, technological advancements, and regional advantages for each type of pharmaceutical product, including small molecule drugs, biologics, and biosimilars.

Market growth figures, such as market share percentages, revenue, and growth rates (e.g., CAGR), are provided for each segment over the specified period (2019-2023). The report covers various segments

Type of Alzheimers Disease Drug analyzed in this report are as follows:

• Centrally Acting AChE Inhibintors
• NMDA Antagonists

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Alzheimers Disease Drug Industry. Request a Free Sample PDF!

Application Segment Analysis of Alzheimers Disease Drug Market

This report analyzes revenue growth in the pharma and healthcare industry at global, regional, and national levels, highlighting trends and opportunities for each application. It explores how sectors like pharmaceuticals, therapy, and healthcare monitoring use innovations to address healthcare needs. Key factors include market size, revenue contributions, technological advancements (e.g., AI-driven diagnostics), and regulatory considerations. The report also covers the value chain, identifying key players and processes within the industry. For more information, please request a sample or contact our research team.

Some of the key Application of Alzheimers Disease Drug are:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Alzheimers Disease Drug Type of Disease Segment Analysis

Late-onset Alzheimer's is the most common form of the disease, which happens to people ages 65 and older. Familial Alzheimer's disease is a form of Alzheimer's disease which is linked to genes. In families that are affected, members of at least two generations have had the disease. FAD makes up less than 1% of all cases of Alzheimer's.

• Early-Onset
• Late-Onset
• Familial

Alzheimers Disease Drug Drugs Type Segment Analysis

Cholinesterase inhibitors are most prescribed type of drugs to treat symptoms related to memory, thinking, language, judgment and other thought processes. These medications prevent the breakdown of acetylcholine, a chemical messenger important for memory and learning. These drugs support communication between nerve cells. Thus, it held the largest revenue share of over 57%.
In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc., for the treatment of patients with severe dementia of Alzheimer’s disease (AD).

• Cholinesterase Inhibitors
• NMDA Receptor Antagonists

Alzheimers Disease Drug Product Segment Analysis

• Donepezil
• Galantamine
• Rivastigmine
• Memantine
• Others

Alzheimers Disease Drug End-Users Segment Analysis

Hospitals dominates the end-user segment of Alzheimer’s Disease Drug in year 2021. However, homecare will show high growth rate in near future as 90% of Americans ages 65 and older want to stay at home for as long as possible, and this age group is growing rapidly. Moreover, home healthcare companies allow people who require extra care no matter what their age to remain in their homes, reducing the burden otherwise shouldered by healthcare facilities, hospitals, assisted living or rehabilitation centres, and nursing homes.

• Hospitals
• Specialty Clinics
• Homecare

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion